查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
片段抗體市場規模、份額和趨勢分析報告：特異性（單克隆抗體、多克隆抗體）、類型、治療、應用、地區、分部預測，2022-2030
市場調查報告書
商品編碼
1122223

片段抗體市場規模、份額和趨勢分析報告：特異性（單克隆抗體、多克隆抗體）、類型、治療、應用、地區、分部預測，2022-2030

Antibody Fragments Market Size, Share & Trends Analysis Report By Specificity (Monoclonal Antibodies, Polyclonal Antibodies), By Type, By Therapy, By Application, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

片段抗體市場增長及趨勢

根據 Grand View Research, Inc. 的一份新報告，到 2030 年，全球片段抗體市場規模預計將達到 113.6 億美元，從 2022 年到 2030 年，複合年增長率為 5.9%。由於人口老齡化和社會行為的變化，慢性病在全球範圍內穩步增加。城市化進程的加快導致中產階級不斷壯大，人們過著更久坐和不健康的生活方式，從而導致糖尿病等疾病的增加。由於人口顯著增長，預計新興市場將承受最大的患者負擔。

此外，主要市場參與者的投資增加有助於行業的增長。例如，2020 年 6 月，范德比爾特大學醫學中心與阿斯利康合作，將該公司的冠狀病毒中和抗體推進臨床開發，作為治療和預防 COVID-19 的可能聯合療法。預計這些因素將在未來幾年推動市場。

抗體是檢測分子和蛋白質的重要工具。儘管對於大多數免疫分析應用來說，全抗體是首選，但一些實驗僅受益於抗體片段，例如 F(ab')2 和 Fab。單克隆抗體是一類重要的被批准用於治療各種癌症的治療劑。超過 80 種抗體已被批准用於各種疾病適應症，使這些抗體成為最大的生物製藥類別。更小、更多抗原結合抗體片段的引入正在快速增長，並對行業產生積極影響。

由於較低的製造和純化成本，預計片段抗體也將優於全鏈抗體。使用片段抗體治療某些疾病可能會受到嚴格的 ICD-10 法規的限制。然而，針對嚴重疾病的片段抗體臨床開發的新進展可能會提供重要的市場增長機會。

片段抗體市場報告亮點

根據特異性，單克隆抗體在 2021 年佔最大份額，因為它們被認為是推薦用於治療多種形式惡性腫瘤的重要治療藥物類別。

按類型劃分，scFv 細分市場預計將在未來幾年見證最快的增長。scFv 與它們的親本 mAb 相比具有幾個優點，包括多價性、異質性生產力、低分子量和多聚體。

通過治療，單克隆抗體細分市場將在 2021 年引領市場。雷珠單抗（Lucentis）將在 2021 年擁有最大的收入份額，因為它用於治療糖尿病性黃斑水腫、新生血管（濕性）年齡相關性黃斑變性（AMD）等引起的視力障礙。

通過應用，由於隨著全球癌症患病率的上升，越來越多地採用片段抗體用於治療目的，預計腫瘤學領域將在預測期內增長最快。

2021 年，北美主導市場，由於免疫缺陷疾病的增加，對用於研究目的的片段抗體的需求不斷增加。

由於私人和公共合作夥伴對生物技術和藥物研究的投資增加，預計亞太地區未來將顯著增長。這刺激了片段抗體的採用。

目錄

第一章執行摘要

  • 市場快照
  • 競爭環境
  • 分部展望

第二章研究方法論

  • 信息採購
  • 信息或數據分析
  • 市場製定和驗證

3. 片段抗體市場變量、趨勢和範圍

  • 母市場分析
  • 市場動態
    • 市場驅動力分析
      • 感染和慢性病的患病率增加
      • 片段抗體優於其他選擇
      • 增加對製藥和生物技術研究的公共和私人投資
    • 市場約束分析
      • 片段抗體純化的障礙

4 片段抗體市場：細分分析，按特異性，2018-2030 年（百萬美元）

  • 定義和範圍
  • 全球片段抗體市場，按特異性，2018-2030 年（百萬美元）
  • 市場規模和預測、趨勢分析，2018 年至 2030 年，百萬美元
    • 單克隆抗體
    • 多克隆抗體

5. 片段抗體市場：細分分析，按類型，2018-2030 年（百萬美元）

  • 定義和範圍
  • 2018-2030 年按類型分列的全球片段抗體市場（百萬美元）
  • 市場規模和預測，趨勢分析，2018-2030
    • 驚人
    • 單鏈抗體
    • 抗體
    • 其他

6. 片段抗體市場：細分分析，按療法，2018-2030 年（百萬美元）

  • 定義和範圍
  • 全球片段抗體市場，按療法，2018-2030 年（百萬美元）
  • 2018-2030 年市場規模和預測、趨勢分析（百萬美元）
    • Monoclonal Antibodies
    • Praxbind (idarucizumab)
    • Ranibizumab (Lucentis)
    • Certolizumab pegol (Cimzia)
    • Iodine (1311) Metuximab/Licartin
    • Beovu (brolucizumab-dbl)
    • Cablivi (caplacizumab-yhdp)
    • blinatumomab/brinsite
    • PAB
    • CroFab
    • Anavip
    • Anascope
    • Botulism Antitoxin Heptavalent (HBAT)
    • Digibind
    • DigiFab
    • Pipeline
    • AFM13
    • HPN-424
    • MGD007
    • Tebotelimab (MGD013)
    • Bentracimab (PB2452)
    • Flotetuzumab (MGD006)
    • AK104
    • Ozoralizumab
    • Sonelokimab (ALX0761)

7. 片段抗體市場：細分分析，按應用，2018-2030 年（百萬美元）

  • 定義和範圍
  • 2018-2030年按應用分列的全球片段抗體市場（百萬美元）
  • 2018-2030 年市場規模和預測、趨勢分析（百萬美元）
    • 癌症
    • 免疫缺陷
    • 其他

8. 片段抗體市場：區域市場分析，2018-2030（百萬美元）

  • 定義和範圍
  • 2021 年和 2030 年區域市場份額分析
  • 區域市場儀表板
  • 區域市場：主要參與者
  • 2018-2030 年市場規模、預測和趨勢分析
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 俄羅斯
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 韓國
    • 新加坡
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國

第 9 章 競爭格局

  • 戰略框架
  • 市場參與的分類
  • 公司簡介
    • Pfizer Inc
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Sanofi
      • 公司簡介
      • Albynx
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Novartis AG
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Genentech, Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • AbbVie Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Bristol-Myers Squibb Company
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Johnson & Johnson Services, Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Lilly
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
Product Code: GVR-4-68039-973-2

Antibody Fragments Market Growth & Trends:

The global antibody fragments market size is expected to reach USD 11.36 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 5.9% from 2022 to 2030. There has been a steady increase in chronic conditions across the globe owing to the increasing geriatric population and societal behavior changes. The expediting urbanization is leading to the growth of the middle class resulting in people adopting a more sedentary and unhealthier lifestyle, in turn, causing an increase in diseases such as diabetes. The emerging markets are predicted to hold the largest patient burden owing to the significant population growth.

Furthermore, growing investments by the key market players have contributed to the industry growth. For instance, in June 2020, Vanderbilt University Medical Center collaborated with AstraZeneca to advance the company's coronavirus-neutralizing antibodies into clinical development as a possible combination therapy for the treatment and prevention of COVID-19. These factors would drive the market in the coming years.

Antibodies are an important tool for molecular and protein detection. Even though whole antibodies are preferable for most immunoassay applications, the performance for some experiments is only enhanced by antibody fragments, such as F(ab')2 and Fab. Monoclonal antibodies are a significant class of therapeutic drugs that have received approval to treat various cancers. With more than 80 antibodies already approved for use in various disease indications, these antibodies represent the largest class of biopharmaceuticals. The introduction of smaller, antigen-binding antibody fragments has been growing at a fast pace, which is impacting the industry positively.

Antibody fragments are also anticipated to be preferred over full-chain antibodies due to their lower manufacturing and purification costs. The use of antibody fragments for the treatment of a specific disease may be constrained by strict ICD-10 rules. However, the new advancements in the clinical development of antibody fragments for serious diseases may offer significant market growth opportunities.

Antibody Fragments Market Report Highlights:

  • By specificity, monoclonal antibodies held the largest share in 2021 as they are considered a significant class of therapeutic agents recommended in the therapy of several forms of malignancies
  • Based on type, the scFv segment is anticipated to witness the fastest growth in the coming years. They provide several advantages such as multivalency, heterologous production, low molecular weight, and multimeric form over the parent mAb
  • By therapy, the monoclonal antibodies segment led the market in 2021. Ranibizumab (Lucentis) captured the largest revenue share in 2021 as these are used for the treatment of visual impairment due to diabetic macular edema, neovascular (wet) age-related macular degeneration (AMD), and others
  • By application, the cancer segment is expected to witness the fastest growth over the forecast period owing to the increasing prevalence of cancer globally, which is resulting in the increasing adoption of antibody fragments for therapeutic purposes
  • North America dominated the market in 2021 owing to the increasing prevalence of immunodeficiency diseases, which has led to the increasing demand for antibody fragments for research purposes
  • Asia Pacific is expected to grow considerably in the future owing to increasing private and public partnership investments in biotech and pharmaceutical research. This has fueled the adoption of antibody fragments

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Competition Milieu
  • 1.3. Segment Outlook

Chapter 2. Research Methodology

  • 2.1. Information Procurement
  • 2.2. Information or Data Analysis
  • 2.3. Market Formulation & Validation

Chapter 3. Antibody Fragments Market Variables, Trends & Scope

  • 3.1. Parent Market Analysis
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of infectious and chronic diseases
      • 3.2.1.2. Antibody fragments are preferred over other alternatives
      • 3.2.1.3. Increasing public-private investments for pharma and biotech research
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Obstacles in the purification of antibody fragments

Chapter 4. Antibody Fragments Market: Segment Analysis, By Specificity, 2018 - 2030 (USD Million)

  • 4.1. Definitions & Scope
  • 4.2. Global Antibody Fragments Market, By Specificity, 2018 to 2030 (USD Million)
  • 4.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 USD Million
    • 4.3.1. Monoclonal Antibodies
      • 4.3.1.1. Global Antibody Fragments Market, Monoclonal Antibodies, 2018 to 2030 (USD Million)
    • 4.3.2. Polyclonal Antibodies
      • 4.3.2.1. Global Antibody Fragments Market, Monoclonal Antibodies, 2018 to 2030 (USD Million)

Chapter 5. Antibody Fragments Market: Segment Analysis, By Type, 2018 - 2030 (USD Million)

  • 5.1. Definitions & Scope
  • 5.2. Global Antibody Fragments Market, By Type, 2018 to 2030 (USD Million)
  • 5.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 5.3.1. FAB
      • 5.3.1.1. Global Antibody Fragments Market, FAB, 2018 to 2030 (USD Million)
    • 5.3.2. scFv
      • 5.3.2.1. Global Antibody Fragments Market,scFv, 2018 to 2030 (USD Million)
    • 5.3.3. sdAb
      • 5.3.3.1. Global Antibody Fragments Market, sdAb, 2018 to 2030 (USD Million)
    • 5.3.4. Others
      • 5.3.4.1. Global Antibody Fragments Market, others, 2018 to 2030 (USD Million)

Chapter 6. Antibody Fragments Market: Segment Analysis, By Therapy, 2018 - 2030 (USD Million)

  • 6.1. Definitions & Scope
  • 6.2. Global Antibody Fragments Market, By Therapy, 2018 to 2030 (USD Million)
  • 6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
    • 6.3.1. Monoclonal Antibodies
    • 6.3.2. Praxbind (idarucizumab)
      • 6.3.2.1. Global Antibody Fragments Market, Praxbind (idarucizumab), 2018 to 2030 (USD Million)
    • 6.3.3. Ranibizumab (Lucentis)
      • 6.3.3.1. Global Antibody Fragments Market, Ranibizumab (Lucentis), 2018 to 2030 (USD Million)
    • 6.3.4. Certolizumab pegol (Cimzia)
      • 6.3.4.1. Global Antibody Fragments Market, Certolizumab pegol (Cimzia), 2018 to 2030 (USD Million)
    • 6.3.5. Iodine (1311) Metuximab/ Licartin
      • 6.3.5.1. Global Antibody Fragments Market, Iodine (1311) Metuximab/ Licartin, 2018 to 2030 (USD Million)
    • 6.3.6. Beovu (brolucizumab-dbll)
      • 6.3.6.1. Global Antibody Fragments Market, Beovu (brolucizumab-dbll), 2018 to 2030 (USD Million)
    • 6.3.7. Cablivi (caplacizumab-yhdp)
      • 6.3.7.1. Global Antibody Fragments Market, Cablivi (caplacizumab-yhdp), 2018 to 2030 (USD Million)
    • 6.3.8. Blinatumomab/ Blincyto
      • 6.3.8.1. Global Antibody Fragments Market, Blinatumomab/ Blincyto, 2018 to 2030 (USD Million)
    • 6.3.9. PAB
    • 6.3.10. CroFab
      • 6.3.10.1. Global Antibody Fragments Market, CroFab, 2018 to 2030 (USD Million)
    • 6.3.11. Anavip
      • 6.3.11.1. Global Antibody Fragments Market, Anavip, 2018 to 2030 (USD Million)
    • 6.3.12. Anascorp
      • 6.3.12.1. Global Antibody Fragments Market, Anascorp, 2018 to 2030 (USD Million)
    • 6.3.13. Botulism Antitoxin Heptavalent (HBAT)
      • 6.3.13.1. Global Antibody Fragments Market, Botulism Antitoxin Heptavalent (HBAT), 2018 to 2030 (USD Million)
    • 6.3.14. Digibind
      • 6.3.14.1. Global Antibody Fragments Market, Digibind, 2018 to 2030 (USD Million)
    • 6.3.15. DigiFab
      • 6.3.15.1. Global Antibody Fragments Market, DigiFab, 2018 to 2030 (USD Million)
    • 6.3.16. Pipeline
    • 6.3.17. AFM13
      • 6.3.17.1. Global Antibody Fragments Market, AFM13, 2018 to 2030 (USD Million)
    • 6.3.18. HPN-424
      • 6.3.18.1. Global Antibody Fragments Market, HPN-424, 2018 to 2030 (USD Million)
    • 6.3.19. MGD007
      • 6.3.19.1. Global Antibody Fragments Market, MGD007, 2018 to 2030 (USD Million)
    • 6.3.20. Tebotelimab (MGD013)
      • 6.3.20.1. Global Antibody Fragments Market, Tebotelimab (MGD013), 2018 to 2030 (USD Million)
    • 6.3.21. Bentracimab (PB2452)
      • 6.3.21.1. Global Antibody Fragments Market, Bentracimab (PB2452), 2018 to 2030 (USD Million)
    • 6.3.22. Flotetuzumab (MGD006)
      • 6.3.22.1. Global Antibody Fragments Market, Flotetuzumab (MGD006), 2018 to 2030 (USD Million)
    • 6.3.23. AK104
      • 6.3.23.1. Global Antibody Fragments Market, AK104, 2018 to 2030 (USD Million)
    • 6.3.24. Ozoralizumab
      • 6.3.24.1. Global Antibody Fragments Market, Ozoralizumab, 2018 to 2030 (USD Million)
    • 6.3.25. Sonelokimab (ALX0761)
      • 6.3.25.1. Global Antibody Fragments Market, Sonelokimab (ALX0761), 2018 to 2030 (USD Million)

Chapter 7. Antibody Fragments Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 7.1. Definitions & Scope
  • 7.2. Global Antibody Fragments Market, By Application, 2018 to 2030 (USD Million)
  • 7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
    • 7.3.1. Cancer
      • 7.3.1.1. Global Antibody Fragments Market, Cancer, 2018 to 2030 (USD Million)
    • 7.3.2. Immunodeficiency
      • 7.3.2.1. Global Antibody Fragments Market, Immunodeficiency, 2018 to 2030 (USD Million)
    • 7.3.3. Others
      • 7.3.3.1. Global Antibody Fragments Market, Others, 2018 to 2030 (USD Million)

Chapter 8. Antibody Fragments Market: Regional Market Analysis, By Region, 2018 - 2030 (USD Million)

  • 8.1. Definitions & Scope
  • 8.2. Regional market share analysis, 2021&2030
  • 8.3. Regional Market Dashboard
  • 8.4. Regional Market: Key Players
  • 8.5. Market Size, & Forecasts, and Trend Analysis, 2018 to 2030
  • 8.6. North America
    • 8.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.6.5. U.S.
      • 8.6.5.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.6.5.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.6.5.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.6.5.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.6.6. Canada
      • 8.6.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.6.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.6.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.6.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.7. Europe
    • 8.7.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.7.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.7.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.7.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.7.5. Germany
      • 8.7.5.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.7.5.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.7.5.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.7.5.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.7.6. U.K.
      • 8.7.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.7.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.7.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.7.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.7.7. France
      • 8.7.7.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.7.7.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.7.7.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.7.7.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.7.8. Italy
      • 8.7.8.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.7.8.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.7.8.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.7.8.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.7.9. Spain
      • 8.7.9.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.7.9.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.7.9.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.7.9.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.7.10. Russia
      • 8.7.10.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.7.10.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.7.10.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.7.10.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.8. Asia Pacific
    • 8.8.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.8.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.8.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.8.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.8.5. China
      • 8.8.5.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.8.5.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.8.5.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.8.5.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.8.6. Japan
      • 8.8.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.8.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.8.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.8.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.8.7. India
      • 8.8.7.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.8.7.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.8.7.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.8.7.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.8.8. Australia
      • 8.8.8.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.8.8.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.8.8.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.8.8.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.8.9. South Korea
      • 8.8.9.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.8.9.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.8.9.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.8.9.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.8.10. Singapore
      • 8.8.10.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.8.10.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.8.10.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.8.10.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.9. Latin America
    • 8.9.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.9.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.9.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.9.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.9.5. Mexico
      • 8.9.5.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.9.5.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.9.5.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.9.5.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.9.6. Brazil
      • 8.9.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.9.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.9.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.9.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.9.7. Argentina
      • 8.9.7.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.9.7.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.9.7.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.9.7.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
  • 8.10. Middle East & Africa
    • 8.10.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
    • 8.10.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
    • 8.10.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
    • 8.10.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.10.5. South Africa
      • 8.10.5.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.10.5.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.10.5.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.10.5.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.10.6. Saudi Arabia
      • 8.10.6.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.10.6.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.10.6.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.10.6.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)
    • 8.10.7. UAE
      • 8.10.7.1. Market estimates and forecast, by Specificity, 2018 - 2030 (USD Million)
      • 8.10.7.2. Market estimates and forecast, By Type, 2018 - 2030 (USD Million)
      • 8.10.7.3. Market estimates and forecast, by Therapy, 2018 - 2030 (USD Million)
      • 8.10.7.4. Market estimates and forecast, by Application, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Strategy Framework
  • 9.2. Market Participation Categorization
  • 9.3. Company Profile
    • 9.3.1. Pfizer Inc
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Sanofi
      • 9.3.2.1. Company Overview
      • 9.3.2.1.1. Albynx
      • 9.3.2.1.1.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Novartis AG
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Genentech, Inc.
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. AbbVie Inc.
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Bristol-Myers Squibb Company
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Johnson & Johnson Services, Inc.
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Lilly
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives

List of Tables

  • Table 1 Global Antibody Fragments Market, By Region, 2018 - 2030 (USD Million)
  • Table 2 Global Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 3 Global Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 4 Global Antibody Fragments Market, By Therapy 2018 - 2030 (USD Million)
  • Table 5 Global Antibody Fragments Market, By Application 2018 - 2030 (USD Million)
  • Table 6 North America Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 7 North America Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 8 North America Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 9 North America Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 10 U.S. Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 11 U.S. Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 12 U.S. Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 13 U.S. Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 14 Canada Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 15 Canada Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 17 Canada Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 18 Europe Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 19 Europe Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 20 Europe Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 21 Europe Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 22 U.K. Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 23 U.K. Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 24 U.K. Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 25 U.K. Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 26 Germany Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 27 Germany Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 28 Germany Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 29 Germany Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 30 France Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 31 France Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 32 France Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 33 France Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 34 Italy Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 35 Italy Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 36 Italy Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 37 Italy Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 38 Spain Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 39 Spain Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 40 Spain Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 41 Spain Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 42 Russia Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 43 Russia Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 44 Russia Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 46 Russia Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 51 Japan Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 52 Japan Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 53 Japan Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 54 Japan Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 55 China Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 56 China Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 57 China Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 58 China Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 59 India Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 60 India Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 61 India Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 62 India Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 63 Australia Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 64 Australia Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 65 Australia Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 66 Australia Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 67 South Korea Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 68 South Korea Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 69 South Korea Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 70 South Korea Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 71 Singapore Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 72 Singapore Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 73 Singapore Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 74 Singapore Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 75 Latin America Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 76 Latin America Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 77 Latin America Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 78 Latin America Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 79 Brazil Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 80 Brazil Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 81 Brazil Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 82 Brazil Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 83 Mexico Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 84 Mexico Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 85 Mexico Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 86 Mexico Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 87 Argentina Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 88 Argentina Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 89 Argentina Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 90 Argentina Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 91 Middle East & Africa Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 92 Middle East & Africa Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 93 Middle East & Africa Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 94 Middle East & Africa Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 95 South Africa Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 96 South Africa Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 97 South Africa Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 98 South Africa Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 99 Saudi Arabia Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 100 Saudi Arabia Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 101 Saudi Arabia Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 102 Saudi Arabia Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)
  • Table 103 UAE Antibody Fragments Market, By Specificity, 2018 - 2030 (USD Million)
  • Table 104 UAE Antibody Fragments Market, By Type, 2018 - 2030 (USD Million)
  • Table 105 UAE Antibody Fragments Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 106 UAE Antibody Fragments Market, By Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Antibody fragments market segmentation
  • Fig. 8 Market driver relevance analysis (Current & future impact)
  • Fig. 9 Market restraint relevance analysis (Current & future impact)
  • Fig. 10 Market challenge relevance analysis (Current & future impact)
  • Fig. 11 Penetration & growth prospect mapping
  • Fig. 12 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 13 Porter's Five Forces analysis
  • Fig. 14 Market penetration vs growth prospect mapping
  • Fig. 15 Antibody fragments market: Specificity outlook and key takeaways
  • Fig. 16 Antibody fragments market: Specificity movement analysis
  • Fig. 17 Monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Polyclonal antibodies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Antibody fragments market: Type outlook and key takeaways
  • Fig. 20 Antibody fragments market: Type movement analysis
  • Fig. 21 FAB market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 scFv market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 sdAb market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Antibody fragments market: Therapy outlook and key takeaways
  • Fig. 26 Antibody fragments market: Therapy movement analysis
  • Fig. 27 Monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 PAB market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Pipeline market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Antibody fragments market: Application outlook and key takeaways
  • Fig. 31 Antibody fragments market: Application movement analysis
  • Fig. 32 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Immunodeficiency market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 Regional outlook, 2021 & 2030
  • Fig. 37 North America antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 39 Canada antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 40 Europe antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 41 U.K. antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 42 Germany antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 43 Italy antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 44 Spain antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 45 France antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 46 Russia antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 49 China antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 50 India antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 51 Australia antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 53 Singapore antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 56 Mexico antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 57 Argentina antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 58 MEA antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 60 Saudi Arabia antibody fragments market, 2018 - 2030 (USD Million)
  • Fig. 61 UAE antibody fragments market, 2018 - 2030 (USD Million)